Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Barbara Mroczko, Magdalena Groblewska, Ala Litman‐Zawadzka, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 1884-1884
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species
Xu‐Qiao Chen, William C. Mobley
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 247
A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain
Shaomin Li, Dennis J. Selkoe
Journal of Neurochemistry (2020) Vol. 154, Iss. 6, pp. 583-597
Open Access | Times Cited: 212
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar, John A. Hey, Aidan Power, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6355-6355
Open Access | Times Cited: 136
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Francesca R. Buccellato, Marianna D’Anca, Gianluca Martino Tartaglia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13900-13900
Open Access | Times Cited: 45
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases
Dillon J. Rinauro, Fabrizio Chiti, Michele Vendruscolo, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Liver Dysfunction as a Novel Player in Alzheimer’s Progression: Looking Outside the Brain
Lisbell D. Estrada, Pablo Ahumada, Daniel Cabrera, et al.
Frontiers in Aging Neuroscience (2019) Vol. 11
Open Access | Times Cited: 123
The Toxicity and Polymorphism of β-Amyloid Oligomers
Yaru Huang, Rui‐tian Liu
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4477-4477
Open Access | Times Cited: 118
Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery
Francesca R. Buccellato, Marianna D’Anca, Chiara Fenoglio, et al.
Antioxidants (2021) Vol. 10, Iss. 9, pp. 1353-1353
Open Access | Times Cited: 96
Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
Amanda Cano, Patric Turowski, Miren Ettcheto, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 86
Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer’s disease
Martina Gabrielli, Ilaria Prada, Pooja Joshi, et al.
Brain (2022) Vol. 145, Iss. 8, pp. 2849-2868
Open Access | Times Cited: 61
Electrocatalysis of Copper Sulfide Nanoparticle-Engineered Covalent Organic Frameworks for Ratiometric Electrochemical Detection of Amyloid-β Oligomer
Yana Chen, Shuangling Wang, Jujie Ren, et al.
Analytical Chemistry (2022) Vol. 94, Iss. 32, pp. 11201-11208
Closed Access | Times Cited: 44
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Sandra Cetin, Damijan Knez, Stanislav Gobec, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 149, pp. 112924-112924
Open Access | Times Cited: 42
Imaging Amyloid‐β Membrane Interactions: Ion‐Channel Pores and Lipid‐Bilayer Permeability in Alzheimer's Disease
John H. Viles
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 25
Open Access | Times Cited: 40
Alzheimer’s disease: a mini-review for the clinician
Rishi S. Madnani
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 23
Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 916-916
Open Access | Times Cited: 22
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Jangampalli Adi Pradeepkiran, Javaria Baig, Md Ariful Islam, et al.
Aging and Disease (2024)
Open Access | Times Cited: 14
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Martí Colom‐Cadena, Jamie Toombs, Elizabeth Simzer, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 13
A Combinational Therapy for Preventing and Delaying the Onset of Alzheimer’s Disease: A Focus on Probiotic and Vitamin Co-Supplementation
Omme Fatema Sultana, Raksa Andalib Hia, P. Hemachandra Reddy
Antioxidants (2024) Vol. 13, Iss. 2, pp. 202-202
Open Access | Times Cited: 10
The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
Barbara Mroczko, Magdalena Groblewska, Ala Litman‐Zawadzka
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 19, pp. 4661-4661
Open Access | Times Cited: 66
microRNAs as Early Biomarkers of Alzheimer’s Disease: A Synaptic Perspective
Dolores Siedlecki‐Wullich, Alfredo J. Miñano‐Molina, José Rodrı́guez-Álvarez
Cells (2021) Vol. 10, Iss. 1, pp. 113-113
Open Access | Times Cited: 55
Amyloid beta acts synergistically as a pro-inflammatory cytokine
Thomas J. LaRocca, Alyssa N. Cavalier, Christine M. Roberts, et al.
Neurobiology of Disease (2021) Vol. 159, pp. 105493-105493
Open Access | Times Cited: 46
Amyloid β / PKC-dependent alterations in NMDA receptor composition are detected in early stages of Alzheimer´s disease
Carolina Ortiz-Sanz, Uxue Balantzategi, Tania Quintela‐López, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 30
The Complex Interplay between Toxic Hallmark Proteins, Calmodulin-Binding Proteins, Ion Channels, and Receptors Involved in Calcium Dyshomeostasis in Neurodegeneration
Danton H. O’Day
Biomolecules (2024) Vol. 14, Iss. 2, pp. 173-173
Open Access | Times Cited: 6
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease
Gilbert M. Rishton, Gary C. Look, Zhi‐Jie Ni, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 9, pp. 1389-1395
Open Access | Times Cited: 33
A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies
Tanja J. de Rijke, M. H. Edwina Doting, Saskia van Hemert, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top